BLRX - BioLineRx - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

1.19B

Cash

32.82M

Avg Qtr Burn

-8.016M

Short % of Float

0.12%

Insider Ownership

0.00%

Institutional Own.

5.24%

Qtr Updated

06/30/23

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
APHEXDA®(Motixafortide )(BL-8040) (CXCR4 antagonist) Details Multiple myeloma, Stem cell mobilization	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Motixafortide (BL-8040) w/ cemiplimab Details Solid tumor/s, Pancreatic cancer, Cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AGI-134 Details Solid tumor/s, Cancer	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Motixafortide (BL-8040) (CXCR4 antagonist) Details Solid tumor/s, Pancreatic cancer, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Motixafortide (BL-8040) (CXCR4 antagonist) Details Acute myeloid leukemia	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.